Ignite Creation Date:
2025-12-24 @ 2:55 PM
Ignite Modification Date:
2026-02-20 @ 1:34 AM
Study NCT ID:
NCT04666259
Status:
COMPLETED
Last Update Posted:
2025-10-16
First Post:
2020-12-07
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation
Sponsor:
Novartis Pharmaceuticals
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Chronic Myelogenous Leukemia - Chronic Phase | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | CML | View |
| None | T315I mutation | View |
| None | CP | View |
| None | Asciminib, | View |
| None | BCR-ABL, | View |
| None | ABL001, | View |
| None | CML-AP, | View |
| None | ELN | View |
| None | MMR | View |
| None | Molecular Response | View |
| None | MR4.5 | View |
| None | MR4 | View |
| None | RQ-PCR | View |
| None | AIM4CML, | View |
| None | tyrosine Kinase Inhibitor | View |
| None | TKI | View |
| None | adult | View |